Cordium Pharmaceuticals Pvt Ltd is an India-based pharmaceutical exporter and supplier providing a range of oncology medicines for international pharmaceutical buyers. The company supports inquiries for Regorafenib Tablets supply to the USA from India, subject to applicable U.S. pharmaceutical regulations, product eligibility, prescription requirements, and import controls.
Regorafenib Tablets – Product Overview
Regorafenib is an oral multikinase inhibitor used in the treatment of certain advanced cancers. In the United States, the FDA-approved labeling for STIVARGA (regorafenib) includes indications for eligible adults with metastatic colorectal cancer (CRC), locally advanced or metastatic gastrointestinal stromal tumor (GIST), and hepatocellular carcinoma (HCC) previously treated with sorafenib.
Regorafenib works by inhibiting multiple kinase pathways involved in tumor growth and angiogenesis. Because it is a prescription oncology medicine, treatment decisions should be made by a qualified healthcare professional according to the patient's diagnosis and treatment history.
Regorafenib Tablets Strength
Regorafenib tablets are commonly supplied in 40 mg strength. The U.S. prescribing information lists 40 mg tablets as the dosage form and strength. The labeled regimen for STIVARGA is 160 mg once daily for the first 21 days of a 28-day cycle, although dose modifications may be required according to tolerability and clinical circumstances.
Patients should follow their oncologist's instructions and should not alter the prescribed dose independently.
Regorafenib Uses
Regorafenib may be prescribed for eligible adult patients with:
- Metastatic colorectal cancer after specified previous therapies
- Locally advanced, unresectable or metastatic GIST after prior imatinib and sunitinib
- Hepatocellular carcinoma after previous sorafenib treatment
The appropriate treatment depends on the patient's medical condition, previous therapies and physician's assessment.
Safety and Medical Supervision
Regorafenib has important safety considerations. The current U.S. prescribing information contains a boxed warning concerning hepatotoxicity, including severe and potentially fatal liver injury. Liver function should be monitored before and during treatment. Other important risks include hypertension, hemorrhage, infections, dermatologic toxicity and gastrointestinal complications.
Regorafenib should therefore be used only under appropriate medical supervision.
Regorafenib Tablets Supply to USA from India
Cordium Pharmaceuticals Pvt Ltd supports Regorafenib Tablets supply from India to international pharmaceutical buyers, including inquiries associated with the USA. The company can assist with product availability, quotations, packaging information and export documentation, depending on the product and applicable regulatory requirements.
For pharmaceutical products entering the United States, buyers and suppliers must ensure compliance with applicable FDA requirements. Product approval status, labeling, establishment requirements and import eligibility can affect whether a particular medicine may legally be supplied or imported into the U.S.
Why Choose Cordium Pharmaceuticals?
- India-based pharmaceutical exporter and supplier
- Experience with international pharmaceutical sourcing
- Focus on oncology and specialty medicines
- Support for international buyer inquiries
- Assistance with product and commercial documentation
- Export coordination from India
- Professional communication for pharmaceutical buyers and distributors
Frequently Asked Questions
Can Regorafenib Tablets be supplied from India to the USA?
Supply to the USA is subject to applicable FDA, prescription-drug, import and other regulatory requirements. Cordium Pharmaceuticals can discuss product availability and export requirements with eligible buyers.
What is Regorafenib used for?
Regorafenib is used for specific advanced cancers, including certain cases of metastatic colorectal cancer, GIST and hepatocellular carcinoma.
What strength of Regorafenib Tablets is available?
The U.S. prescribing information lists 40 mg tablets. Availability, manufacturer and packaging should be confirmed at the time of inquiry.
Is Regorafenib a prescription medicine?
Yes. Regorafenib is an oncology prescription medicine that requires appropriate medical supervision.
How can I inquire about Regorafenib Tablets from India?
International pharmaceutical buyers can contact Cordium Pharmaceuticals Pvt Ltd for current availability, quotation, product specifications, packaging and applicable export requirements.
Regorafenib Tablets Supplier and Exporter from India
For pharmaceutical sourcing requirements, Cordium Pharmaceuticals Pvt Ltd provides support for Regorafenib Tablets supply to USA from India. Buyers can contact Cordium Pharmaceuticals to discuss product availability, pricing, packaging and export documentation, subject to applicable regulations and product eligibility.